Article
Impact of Continuous Ofatumumab Exposure During Pregnancy in Multiple Sclerosis
7 Nov 2024
Abstract excerpt
Objectives: Anti-CD20 therapies are highly effective treatment options for patients with multiple sclerosis (MS), an inflammatory disorder of the CNS commonly affecting women of childbearing age. Anti-CD20 therapies are however unlicensed for use in pregnancy. Belonging to the IgG1 family, anti-CD20 monoclonal antibodies are likely to cross the placenta, especially after the 20th week of gestation. Our objective...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
